Is Actinogen Medical Limited (ATGGF) a Buy, Sell, or Hold?
OTC : ATGGF
Actinogen Medical Limited
$0.0008 USD
$0 (0.0%)
- Volume
- 100
- Average Volume
- 340.14K
- Market Capitalization
- $2.97M
- P/E Ratio
- -7.76
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $1.00
- Year Low
- $0.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.19
Company Overview
OTC
Steven G. Gourlay
Biotechnology
Healthcare
ATGGF
6
AU
USD
Liquidity Metrics
0.04
4.19
4.19
3.12
0.00
Sales & Valuation
$5.49M
30.47
17.14
-10.17
-0.01
Profitability
-$0.0049
-$14.73M
-326.26%
-360.40%
-134.14%
-168.94%
P/E Metrics
-7.76
-0.08
-0.08
Analyst Price Target & Rating
1/5
0 Analysts
%
Financial Health Scores
-20.39
2/9
$6.66M
$10.6M
$2.23M
-$30.23M
Key Metrics (TTM)
$161.12M
29.35
-8.10
4.19
-134.14%
-146.52%
-12.49%
-9.83%
-1351 days
Company Executives
| Name | Title |
|---|---|
| William Edward Souter IPAA | Chief Financial Officer |
| Paul Edward Rolan | Head of Clinical Pharmacology & Lead Physician and Depression |
| Andrew Udell | Chief Commercial Officer |
| Michael Roberts | Head of Investor Relations & Corporate Communications |
| Peter Gordon Webse FCIS FCPA FGIA | Company Secretary |
| Dana C. Hilt | Chief Medical Officer & Member of Depression and Cognition Clinical Advisory Board |
| Fujun Li | Head of Manufacturing |
| Steven G. Gourlay FRACP MBBS | MD, Chief Executive Officer & Director |
Poll Results
No votes yet today — be the first to share your view!
About Actinogen Medical Limited (OTC:ATGGF) Stock
Actinogen Medical Limited is an Australian biotechnology firm specializing in the creation of treatments for neurological and neuropsychiatric conditions linked to abnormal brain cortisol levels. Their primary therapeutic candidate, Xanamem, functions as an inhibitor of the 11ß-HSD1 enzyme. Currently in Phase 2 clinical trials, Xanamem has shown the ability to engage its intended target within the central nervous system. Its development focuses on addressing Alzheimer's disease, cognitive impairment associated with depression, and the anxiety, sleep, and behavioral challenges seen in fragile X syndrome. Founded in 1999, the company, based in Sydney, Australia, operated as Actinogen Limited until its name change to Actinogen Medical Limited in November 2015. ...
Traders see little chance of Hormuz shipping recovery by end of August
2026-08-06 07:02:00
Prediction market traders have cut the odds of a meaningful recovery in shipping through the Strait of Hormuz by the end of this month, despite renewed talk...
Hikma jumps 10% as brokers point to profit beat and undemanding rating
2026-08-06 06:30:00
Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) shares rose 10% to 1,721p after first-half results came in ahead of expectations on profits, with both Peel...
2026-08-06 05:55:00
Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) has outlined the scientific rationale supporting its lead drug candidate Xanamem® (emestedastat) as a potential...
The Small Cap Watch: Healthcare, critical minerals and gold explorers advance projects
2026-08-06 05:49:00
The S&P/ASX Small Ordinaries Index (ASX) closed at 3,482.30 on Wednesday, August 5, gaining 80.50 points or 2.37%. The index has risen 170.20 points, or...
Actinogen Medical advances pivotal XanaMIA trial towards November readout - ICYMI
2026-08-01 06:00:00
Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) earlier this week reported continued progress across its clinical, regulatory and financial programs during the...
Novo Resources expands Wyloo silver targets - ICYMI
2026-07-24 07:40:00
Novo Resources Corp (TSX:NVO, OTCQX:NSRPF, ASX:NVO, FRA:1NOR) earlier this week confirmed that maiden reverse circulation drilling at its Wyloo Polymetallic...
Horizon Gold details A$1.31B Gum Creek NPV - ICYMI
2026-07-24 07:31:00
Horizon Gold Ltd (ASX:HRN, OTC:HZGLF, FRA:HO0) earlier this week confirmed a financially robust development pathway for its 100%-owned Gum Creek Gold...
Resolution Minerals secures second FAST-41 status - ICYMI
2026-07-24 07:10:00
Resolution Minerals Ltd (ASX:RML, OTCQB:RLMLF, FRA:NC3) earlier this week secured US Federal FAST-41 Transparency coverage for its Golden Gate tungsten-gold...
Frequently Asked Questions
-
What is the current Actinogen Medical Limited (ATGGF) stock price?
-
Actinogen Medical Limited(OTC:ATGGF) stock price is $0.0008 in the last trading session. During the trading session, ATGGF stock reached the peak price of $1 while $0.0008 was the lowest point it dropped to. The percentage change in ATGGF stock occurred in the recent session was 0.0% while the dollar amount for the price change in ATGGF stock was $0.
-
ATGGF's industry and sector of operation?
-
The OTC listed ATGGF is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ATGGF?
-
William Edward Souter IPAA | Chief Financial Officer
Paul Edward Rolan | Head of Clinical Pharmacology & Lead Physician and Depression
Andrew Udell | Chief Commercial Officer
Michael Roberts | Head of Investor Relations & Corporate Communications
Peter Gordon Webse FCIS FCPA FGIA | Company Secretary -
How many employees does ATGGF have?
-
Number of ATGGF employees currently stands at 6. ATGGF operates from 109 Pitt Street, Sydney, NSW 2000, AU.
-
Link for ATGGF official website?
-
Official Website of ATGGF is: https://www.actinogen.com.au
-
How do I contact ATGGF?
-
ATGGF could be contacted at phone #61 2 8964 7401 and can also be accessed through its website. ATGGF operates from 109 Pitt Street, Sydney, NSW 2000, AU.
-
How many shares of ATGGF are traded daily?
-
The average number of ATGGF shares traded daily for last 3 months was 340.14K.
-
What is the market cap of ATGGF currently?
-
The market value of ATGGF currently stands at $2.97M with its latest stock price at $0.0008